Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Focus on epithelial ovarian cancer.
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Ozols RF, et al. Among authors: schilder rj. Cancer Cell. 2004 Jan;5(1):19-24. doi: 10.1016/s1535-6108(04)00002-9. Cancer Cell. 2004. PMID: 14749123 Free article. No abstract available.
New therapies for ovarian cancer.
Schilder RJ, Ozols RF. Schilder RJ, et al. Cancer Invest. 1992;10(4):307-15. doi: 10.3109/07357909209032755. Cancer Invest. 1992. PMID: 1352730 Review. No abstract available.
Gynecological cancers.
Boente MP, Schilder R, Ozols RF. Boente MP, et al. Cancer Chemother Biol Response Modif. 1999;18:418-34. Cancer Chemother Biol Response Modif. 1999. PMID: 10800496 Review. No abstract available.
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Schilder RJ, et al. Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16. Gynecol Oncol. 2012. PMID: 22710075 Free PMC article. Clinical Trial.
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Schilder RJ, et al. Clin Cancer Res. 2005 Aug 1;11(15):5539-48. doi: 10.1158/1078-0432.CCR-05-0462. Clin Cancer Res. 2005. PMID: 16061871 Clinical Trial.
Platinum resistance: the role of DNA repair pathways.
Martin LP, Hamilton TC, Schilder RJ. Martin LP, et al. Among authors: schilder rj. Clin Cancer Res. 2008 Mar 1;14(5):1291-5. doi: 10.1158/1078-0432.CCR-07-2238. Clin Cancer Res. 2008. PMID: 18316546 Review.
The management of early ovarian cancer.
Schilder RJ, Boente MP, Corn BW, Lanciano RM, Young RC, Ozols RF. Schilder RJ, et al. Oncology (Williston Park). 1995 Feb;9(2):171-82; discussion 185-7. Oncology (Williston Park). 1995. PMID: 8771099 Free article. Review.
148 results